GI
PCRX icon

Gradient Investments’s Pacira BioSciences PCRX Stock Holding History

Gradient Investments’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-158,610
Closed -$4.54M – 997
2024
Q2 		$4.54M Buy
158,610
+20,183
+15% +$574K 0.1% 151
2024
Q1 		$4.04M Sell
138,427
-1,522
-1% -$46.8K 0.09% 155
2023
Q4 		$4.72M Buy
139,949
+34,723
+33% +$1.02M 0.11% 140
2023
Q3 		$3.23M Buy
105,226
+3,317
+3% +$120K 0.09% 150
2023
Q2 		$4.08M Buy
101,909
+22,160
+28% +$916K 0.11% 142
2023
Q1 		$3.25M Buy
79,749
+8,002
+11% +$318K 0.09% 148
2022
Q4 		$2.77M Buy
71,747
+14,938
+26% +$727K 0.09% 161
2022
Q3 		$3.02M Sell
56,809
-33,153
-37% -$1.84M 0.09% 152
2022
Q2 		$5.25M Sell
89,962
-31,579
-26% -$2.07M 0.15% 135
2022
Q1 		$9.28M Sell
121,541
-18,632
-13% -$1.24M 0.24% 115
2021
Q4 		$8.43M Buy
140,173
+56,725
+68% +$3.13M 0.21% 124
2021
Q3 		$4.67M Buy
83,448
+21,637
+35% +$1.25M 0.13% 143
2021
Q2 		$3.75M Buy
61,811
+6,534
+12% +$414K 0.11% 147
2021
Q1 		$3.87M Buy
+55,277
New +$3.95M 0.13% 142
2020
Q1 		– Sell
-204
Closed -$9K – 1203
2019
Q4 		$9K Hold
204
– – ﹤0.01% 731
2019
Q3 		$8K Hold
204
– – ﹤0.01% 711
2019
Q2 		$9K Buy
+204
New +$8.66K ﹤0.01% 679

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Gradient Investments's PCRX Position: Q3 2024 in Review

Gradient Investments sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 158,610 shares — an estimated $4.54M sold.

Gradient Investments first reported a position in PCRX in Q2 2019 and held it in 17 quarters. The position peaked at $9.28M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Gradient Investments reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Gradient Investments sold 158,610 Pacira BioSciences shares in Q3 2024, an estimated $4.54M.
  • Gradient Investments first reported a position in Pacira BioSciences in Q2 2019 and held it in 17 quarters.
  • Gradient Investments's Pacira BioSciences position peaked at $9.28M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Gradient Investments's 13F filing for Q3 2024, filed 15 Oct 2024.